Trials / Completed
CompletedNCT02061683
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 263 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost 0.03% | Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months. |
Timeline
- Start date
- 2010-04-19
- Primary completion
- 2011-06-24
- Completion
- 2011-06-24
- First posted
- 2014-02-13
- Last updated
- 2019-04-18
- Results posted
- 2014-06-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02061683. Inclusion in this directory is not an endorsement.